| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Pivekimab Basic information |
| Product Name: | Pivekimab | | Synonyms: | Pivekimab;Research Grade Pivekimab(DHD72502);Research Grade Pivekimab;Pivekimab (anti-CD123) | | CAS: | 2234335-84-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Pivekimab Structure]() |
| | Pivekimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Pivekimab Usage And Synthesis |
| Uses | Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN)[1][2]. | | References | [1] Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.
[2] Poussard, et al. Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model. Blood 142 (2023): 2791. |
| | Pivekimab Preparation Products And Raw materials |
|